Medical Weight Loss Program with Mounjaro vs. Wegovy: Differences, Benefits, and Which One Might Be Better for Weight Loss

Obesity and being overweight are chronic conditions that affect millions of people and increase the risk of type 2 diabetes, high blood pressure, cardiovascular disease, and other health problems. In recent years, GLP-1 receptor agonist treatments have brought about a significant change in weight management, offering an effective alternative when diet and exercise alone are not enough.

Among the best-known treatments are Wegovy® (semaglutide) and Mounjaro® (tirzepatide). Although both help with weight loss, there are important differences between them.

What are GLP-1 medications?

GLP-1s are medications that mimic the action of a natural hormone produced by the intestine after eating. This hormone helps to:

• Increase the feeling of fullness.
• Reduce appetite.
• Delay stomach emptying.
• Improve blood glucose control.

As a result, many people naturally eat less, which facilitates gradual weight loss as part of a medically supervised treatment program.

What is Wegovy?

Wegovy contains semaglutide, a GLP-1 receptor agonist specifically designed to treat overweight and obesity in people who meet certain medical criteria.

It is administered via a subcutaneous injection once a week and must always be accompanied by changes in diet, exercise, and professional monitoring.

Its main benefits

• It reduces your appetite.
• It helps control snacking and cravings.
• It promotes clinically significant weight loss.
• It can improve certain risk factors associated with obesity.

What is Mounjaro?

Mounjaro contains tirzepatide, a medication that acts on two hormone receptors (GIP and GLP-1), which enhances its effects on appetite and metabolism.

Like Wegovy, it is administered once a week by injection and requires medical supervision throughout the course of treatment.

Mounjaro vs. Wegovy: Key Differences

Clinical studies suggest that tirzepatide may result in greater average weight loss than semaglutide in certain patients, although the most appropriate treatment always depends on the patient’s medical history, comorbidities, and the specialist’s assessment.